Covid-19ReCOVNCT04653844
RT-PCR Database Analysis for COVID-19 Infections and Re-infection
An observational study of Covid-19 and SARS-CoV Infection, run by University Hospital, Montpellier at 1 site in France.
Trial summary
The SARS-Cov2 pandemic remains associated with many concerns. One of the them is the real frequency of likely re-infection and subsequently the level of protection conferred by the acquired immunity following primary-infection. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Covid-19, SARS-CoV Infection
- How many people
- 7,000,000 participants
- Where
- 1 siteFrance
- Study dates
- 1 Feb 2020to 30 Jan 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: French population with a positive SARS-Cov2 diagnosis documented through a positive RT-PCR result
Who may be able to join
- People with at least one positive SARS-Cov2 RT-PCR result with a known sampling date
Who cannot join
- Patient refusing to participate in research
Trial locations and contacts
1 site in 1 country.
France1 site, 1 recruiting
- Recruiting
Uh Montpellier
Montpellier, 34295
Vincent Foulongne, PHD, 467 330 254 ext. 33, v-foulongne@chu-montpellier.fr
About this study
Official title: SARS-Cov2 (COVID-19) Infection and Reinfection Through the Analysis of a RT-PCR Results Database
The SARS-Cov2 pandemic remains associated with many concerns. One of the them is the real frequency of likely re-infection and subsequently the level of protection conferred by the acquired immunity following primary-infection. We propose to analyze a large set of laboratory data produced since the early beginning of the SARS-Cov2 spread in the French population to identify recurrent infection events and, more generally, gain insight about infection kinetics.
- Conditions
- Covid-19, SARS-CoV Infection
- Keywords
- SARS-Cov2 infection, Positive SARS-Cov2 RT-PCR, SARS-Cov2 immune status, reinfection, kinetics, Rt-PCR, immunity
- Medical subject headings
- COVID-19, Severe Acute Respiratory Syndrome, Reinfection
What is being measured
The primary outcome is the main question the study is designed to answer.
SARS-CoV-2 reinfection rate
SARS-CoV-2 reinfection rate
Measured: 1 day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Dec 2020
- Study start1 Feb 2020
- Primary completion31 Dec 2022 (estimated)
- Study completion30 Jan 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Covid-19Studies of the same condition, open and under way.
- More trials run by University Hospital, MontpellierThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Retrospective
- Enrolment
- 7,000,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Montpellier
- Sponsor type
- University, hospital or other
- Collaborators
- Laboratoire CERBA-MPL, CNRS (MIVEGEC), Nîmes University Hospital
- Responsible party
- Sponsor
- Investigators
- Vincent Foulongne, PhD, Study director, UH MONTPELLIER
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04653844
- Sponsor's protocol ID
- RECHMPL20_0640
- Acronym
- ReCOV
- Status last verified
- Jan 2022
- First submitted
- 3 Dec 2020
- Last updated
- 4 Jan 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: NC
Study at a glance
From the registry record, last updated by the sponsor on 4 Jan 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- SARS-Cov2 (COVID-19) Infection and Reinfection Through the Analysis of a RT-PCR Results Database
- ClinicalTrials.gov ID
- NCT04653844
- Acronym / sponsor ID
- ReCOV / RECHMPL20_0640
- Conditions
- Covid-19, SARS-CoV Infection
- Keywords
- SARS-Cov2 infection, Positive SARS-Cov2 RT-PCR, SARS-Cov2 immune status, reinfection, kinetics, Rt-PCR, immunity
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 7,000,000 participants (estimated)
- Lead sponsor
- University Hospital, MontpellierUniversity, hospital or other
- Collaborators
- Laboratoire CERBA-MPL, CNRS (MIVEGEC), Nîmes University Hospital
- Study start
- 1 Feb 2020 (actual)
- Primary completion
- 31 Dec 2022 (estimated)
- Study completion
- 30 Jan 2023 (estimated)
- First posted
- 4 Dec 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The SARS-Cov2 pandemic remains associated with many concerns. One of the them is the real frequency of likely re-infection and subsequently the level of protection conferred by the acquired immunity following primary-infection. We propose to analyze a large set of laboratory data produced since the early beginning of the SARS-Cov2 spread in the French population to identify recurrent infection events and, more generally, gain insight about infection kinetics.
Study design
- Observational model
- Other
- Time perspective
- Retrospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- French population with a positive SARS-Cov2 diagnosis documented through a positive RT-PCR result
Key inclusion criteria (1 listed)
- People with at least one positive SARS-Cov2 RT-PCR result with a known sampling date
Key exclusion criteria (1 listed)
- Patient refusing to participate in research
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
SARS-CoV-2 reinfection rate
Time frame: 1 day
SARS-CoV-2 reinfection rate
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Jan 2022.
- Individual participant dataSharing planned: Undecided. NC
Related trials for Covid-19
Recruiting
Whole-body Cryotherapy in Those With Chronic Fatigue: A Feasibility Study
ME/CFS, Fibromyalgia (FM)
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruiting
Working Towards Empowered Community-driven Approaches to Increase Vaccination and Preventive Care Engagement
COVID-19
Active, not recruitingObservational study
Epigenetic Changes in Long COVID Patients
Long COVID-19 Syndrome, Long COVID Symptoms
RecruitingPhase 3
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Respiratory Tract Diseases, Influenza (Pandemic)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Vincent Foulongne, PhD study director
UH MONTPELLIER
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Covid-19 and SARS-CoV Infection, run by University Hospital, Montpellier at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 4 Jan 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Samuel Alizon, PhD (610654902 ext. 33, samuel.alizon@cnrs.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
SARS-CoV-2 reinfection rate (time frame: 1 day). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Jan 2022.